- Home
- BDJ vs IMCR Comparison
BDJ vs IMCR Comparison
Compare BDJ & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDJ
- IMCR
- Stock Information
- Founded
- BDJ 2005
- IMCR 2008
- Country
- BDJ United States
- IMCR United Kingdom
- Employees
- BDJ N/A
- IMCR N/A
- Industry
- BDJ Finance Companies
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDJ Finance
- IMCR Health Care
- Exchange
- BDJ Nasdaq
- IMCR Nasdaq
- Market Cap
- BDJ 1.6B
- IMCR 1.7B
- IPO Year
- BDJ N/A
- IMCR 2021
- Fundamental
- Price
- BDJ $8.85
- IMCR $38.06
- Analyst Decision
- BDJ
- IMCR Buy
- Analyst Count
- BDJ 0
- IMCR 9
- Target Price
- BDJ N/A
- IMCR $67.00
- AVG Volume (30 Days)
- BDJ 561.6K
- IMCR 270.5K
- Earning Date
- BDJ 01-01-0001
- IMCR 11-06-2025
- Dividend Yield
- BDJ 8.85%
- IMCR N/A
- EPS Growth
- BDJ N/A
- IMCR N/A
- EPS
- BDJ N/A
- IMCR N/A
- Revenue
- BDJ N/A
- IMCR $379,590,000.00
- Revenue This Year
- BDJ N/A
- IMCR $30.11
- Revenue Next Year
- BDJ N/A
- IMCR $8.89
- P/E Ratio
- BDJ N/A
- IMCR N/A
- Revenue Growth
- BDJ N/A
- IMCR 28.11
- 52 Week Low
- BDJ $6.91
- IMCR $23.15
- 52 Week High
- BDJ $8.66
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- BDJ 38.12
- IMCR 68.71
- Support Level
- BDJ $8.79
- IMCR $34.30
- Resistance Level
- BDJ $8.99
- IMCR $38.17
- Average True Range (ATR)
- BDJ 0.08
- IMCR 1.53
- MACD
- BDJ -0.03
- IMCR 0.60
- Stochastic Oscillator
- BDJ 11.76
- IMCR 97.59
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.